# US 2012/0252794 A1 · Analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252794 A1
- Document ID: US20120252794A1
- Status: Published application
- Kind: A1
- Application number: 13/461,036
- Filed: 2012-05-01
- Published: 2012-10-04
- Earliest claimed: 1997-09-17
- Assignees: Purdue Pharma L.P.
- Inventors: Ronald M. Burch; Paul D. Goldenheim; Richard S. Sackler
- Web page: https://patentgrep.com/patent/US20120252794A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/415: 1,2-Diazoles
- A61K 31/4353: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 31/54: having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 29/02: without antiinflammatory effect
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to the use of a combination of an opioid analgesic together with a COX-2 inhibitor.

## Claims

### Claim 1

A pharmaceutical composition comprising a combination of a COX-2 inhibitor in an amount sufficient to render a therapeutic effect together with an opioid analgesic, except for combinations of the COX-2 inhibitor with an anti-tussive dose of hydrocodone or codeine.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein such that an analgesic effect is attained which is at least about 5 times greater than that obtained with the dose of opioid analgesic alone.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the dose of opioid analgesic would be subtherapeutic if administered without the COX-2 inhibitor.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the opioid analgesic and COX-2 inhibitor are administered orally, via implant, parenterally, sublingually, rectally, topically, or via inhalation.

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the opioid analgesic is selected from the group consisting of alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, cyclazocine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetylbutyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene fentanyl, heroin, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levallorphan, levorphanol, levophenacylmorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, norpipanone, opium, oxycodone, oxymorphone, papavereturn, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propiram, propoxyphene, sufentanil, tilidine, tramadol, salts thereof, complexes thereof; and mixtures of any of the foregoing.

### Claim 6 (depends on 1)

The pharmaceutical composition according to claim 1, wherein said opioid analgesic is selected from the group consisting of mu-agonists, kappa-agonists, mixed mu-agonists/antagonists, mu-antagonist combinations, salts thereof, complexes thereof, and mixtures thereof.

### Claim 7 (depends on 1)

The pharmaceutical composition according to claim 1, which is selected from the group consisting of a tablet; a multiparticulate formulation for oral administration; a solution, suspension or elixer for oral administration; an injectable formulation; an implantable device; a topical preparation; a suppository; a buccal tablet; or an inhalation formulation.

### Claim 8 (depends on 1)

The pharmaceutical composition according to claim 1, which is a solid oral dosage form formulated as a tablet or a capsule.

### Claim 9 (depends on 1)

The pharmaceutical composition according to claim 1, comprising a therapeutically effective or sub-therapeutic amount of an opioid analgesic selected from the group consisting of morphine, methadone, meperidine, levorphanol, codeine, hydrocodone, dihydrocodeine, hydromorphone, oxycodone, oxymorphone, salts thereof, and mixtures of any of the foregoing.

### Claim 10 (depends on 1)

The pharmaceutical composition according to claim 1, wherein said COX-2 inhibitor is selected from the group consisting of celecoxib (SC-58635), DUP-697, flosulide (CGP-28238), meloxicam, Vioxx (L 745,337), 6-methoxy-2 naphthylacetic acid (6-MNA), MK-966, nabumetone, nimesulide, NS-398, SC-5766, SC-58215, T-614, and mixtures thereof.

### Claim 11 (depends on 1)

The pharmaceutical composition according to claim 1, comprising a COX-2 inhibitor in an amount sufficient to render a therapeutic effect together with a dose of hydrocodone which is analgetic if administered without the COX-2 inhibitor.

### Claim 12 (depends on 11)

The pharmaceutical composition according to claim 11, wherein the dose of hydrocodone is preferably from about 15 to about 2000 mg.

### Claim 13 (depends on 1)

The pharmaceutical composition according to claim 1, comprising a COX-2 inhibitor in an amount sufficient to render a therapeutic effect together with a dose of codeine which is analgetic if administered without the COX-2 inhibitor.

### Claim 14 (depends on 13)

The pharmaceutical composition according to claim 13, wherein the dose of codeine is from about 30 to about 400 mg.

### Claim 15 (depends on 1)

The pharmaceutical composition according to claim 1, comprising an opioid analgesic selected from the group consisting morphine, methadone, meperidine, levorphanol, hydromorphone, oxycodone, hydrocodone, and codeine, together with a COX-2 inhibitor selected from the group consisting of celecoxib, flosulide, meloxicam, nabumetone, nimesulide, T614 and MK 966, in the ratios set forth in Table I.

### Claim 16 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the dose of COX-2 inhibitor synergistically potentiates the effect of the opioid analgesic, but the dose of opioid analgesic does not appear to significantly potentiate the effect of the COX-2 inhibitor.

### Claim 17 (depends on 8)

The pharmaceutical composition according to claim 8, wherein the oral solid dosage form includes a sustained release carrier which causes the sustained release of the COX-2 inhibitor, the opioid analgesic, or both the opioid analgesic and the COX-2 inhibitor, when the dosage form contacts gastrointestinal fluid.

### Claim 18

A method of effectively treating pain in humans or other mammals, comprising administering to the patient a therapeutically effective amount of a COX-2 inhibitor together with a dose of an opioid analgesic.

### Claim 19 (depends on 18)

The method of claim 18, wherein the combination provides an analgesic effect which is at least about 5 times greater than that obtained with the dose of opioid analgesic alone.

### Claim 20 (depends on 18)

The method of claim 18, wherein the dose of the COX-2 inhibitor and the opioid analgesic are administered orally.

### Claim 21 (depends on 18)

The method of claim 18, wherein the dose of the COX-2 inhibitor and the opioid analgesic are administered in a single oral dosage form.

### Claim 22 (depends on 18)

The method of claim 18, wherein the dose of opioid analgesic would be sub-therapeutic if administered without the dose of COX-2 inhibitor.

### Claim 23 (depends on 18)

The method of claim 18, wherein the dose of opioid analgesic is effective to provide analgesia alone, but the dose of opioid provides at least a five-fold greater analgesic effect than typically obtained with that dose of opioid alone.

### Claim 24

The use of a pharmaceutical combination of a COX-2 inhibitor together with an opioid analgesic to provide effective pain management in humans.

### Claim 25

The use of a COX-2 inhibitor in the manufacture of a pharmaceutical preparation containing a COX-2 inhibitor and an opioid analgesic for the treatment of pain.

### Claim 26

The use of an opioid analgesic in the manufacture of a pharmaceutical preparation containing a COX-2 inhibitor and an opioid analgesic for the treatment of pain.

### Claim 27 (depends on 18)

The method of claim 18, wherein the COX-2 inhibitor is administered before, simultaneously with, or after administration of the opioid analgesic, such that the dosing interval of the COX-2 inhibitor overlaps with the dosing interval of the opioid analgesic.

### Claim 28

A method of reducing the amount of opioid required to treat a patient affected with pain comprising co-administering with said opioid analgesic an effective amount of a COX-2 inhibitor, to augment the analgesia attributable to said opioid analgesic during at least a portion of the dosage interval of said opioid analgesic.

### Claim 29

A method of reducing the amount of a COX-2 inhibitor required to treat a patient affected with pain, comprising co-administering with said COX-2 inhibitor an effective amount of an opioid analgesic, to augment the analgesia attributable to said COX-2 inhibitor during at least a portion of the dosage interval of said COX-2 inhibitor.
